CompletedPhase 2NCT02110706
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yale University
- Principal Investigator
- Richard J Nowak, MD, MSYale University
- Intervention
- Rituximab(drug)
- Enrollment
- 52 enrolled
- Eligibility
- 21-90 years · All sexes
- Timeline
- 2014 – 2018
Study locations (26)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of California - Davis, Davis, California, United States
- University of California - Los Angeles, Los Angeles, California, United States
- University of Colorado - Denver, Denver, Colorado, United States
- Yale School of Medicine, Department of Neurology, New Haven, Connecticut, United States
- University of Miami School of Medicine, Miami, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Northwestern University, Evanston, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Brigham & Women's Hospital, Boston, Massachusetts, United States
- Washington University, St Louis, Missouri, United States
- SUNY Downstate Medical Center, Brooklyn, New York, United States
- SUNY Buffalo, Buffalo, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Weill Cornell Medical Center, New York, New York, United States
- +11 more locations on ClinicalTrials.gov
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02110706 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.